Patten & Patten’s Aurinia Pharmaceuticals AUPH Stock Holding History

Patten & Patten’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$791K	Sell	46,630 -3,870	-8%	-$61.8K	0.04%	205
2026 Q1	$748K	Sell	50,500 -12,500	-20%	-$183K	0.05%	209
2025 Q4	$1M	Sell	63,000 -6,625	-10%	-$93.9K	0.06%	185
2025 Q3	$769K	Sell	69,625 -2,961	-4%	-$32.3K	0.05%	213
2025 Q2	$615K	Hold	72,586	–	–	0.04%	211
2025 Q1	$584K	Sell	72,586 -2,768	-4%	-$22.4K	0.04%	211
2024 Q4	$677K	Sell	75,354 -17,190	-19%	-$140K	0.04%	199
2024 Q3	$678K	Hold	92,544	–	–	0.05%	196
2024 Q2	$528K	Buy	92,544 +15,429	+20%	+$81.3K	0.04%	211
2024 Q1	$386K	Buy	+77,115	New	+$523K	0.03%	235

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Patten & Patten's AUPH Position: Q2 2026 in Review

Patten & Patten reduced its Aurinia Pharmaceuticals (AUPH) stake by 7.7% in Q2 2026, selling an estimated $61.8K and leaving 46,630 shares worth $791K. The position accounts for 0.04% of the portfolio, ranked #205.

Patten & Patten first reported a position in AUPH in Q1 2024 and has held it in 10 quarters since. The position peaked at $1M in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Patten & Patten held 46,630 shares of Aurinia Pharmaceuticals worth $791K as of Q2 2026.
Patten & Patten sold 3,870 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $61.8K.
Aurinia Pharmaceuticals made up 0.04% of Patten & Patten's portfolio in Q2 2026, its #205 holding.
Patten & Patten first reported a position in Aurinia Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Patten & Patten's Aurinia Pharmaceuticals position peaked at $1M in Q4 2025.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Patten & Patten's 13F filing for Q2 2026, filed 5 Aug 2026.